High Risk for Invasive Meningococcal Disease Among Patients Receiving Eculizumab (Soliris) Despite Receipt of Meningococcal Vaccine
Supporting Files
Public Domain
-
Jul 14 2017
-
Details
-
Journal Article:Morbidity and Mortality Weekly Report (MMWR)
-
Personal Author:
-
Description:Use of eculizumab (Soliris, Alexion Pharmaceuticals), a terminal complement inhibitor, is associated with a 1,000-fold to 2,000-fold increased incidence of meningococcal disease (1). Administration of meningococcal vaccines is recommended for patients receiving eculizumab before beginning treatment (2,3). Sixteen cases of meningococcal disease were identified in eculizumab recipients in the United States during 2008-2016; among these, 11 were caused by nongroupable Neisseria meningitidis. Fourteen patients had documentation of receipt of at least 1 dose of meningococcal vaccine before disease onset. Because eculizumab recipients remain at risk for meningococcal disease even after receipt of meningococcal vaccines, some health care providers in the United States as well as public health agencies in other countries recommend antimicrobial prophylaxis for the duration of eculizumab treatment; a lifelong course of treatment is expected for many patients. Heightened awareness, early care seeking, and rapid treatment of any symptoms consistent with meningococcal disease are essential for all patients receiving eculizumab treatment, regardless of meningococcal vaccination or antimicrobial prophylaxis status.
-
Subjects:
-
Source:MMWR Morbidity Mortal Weekly Rep. 66(27):734-737.
-
Series:
-
DOI:
-
ISSN:0149-2195 (print) ; 1545-861X (digital)
-
Pubmed ID:28704351
-
Pubmed Central ID:PMC5687588
-
Document Type:
-
Place as Subject:
-
Pages in Document:4 pdf pages
-
Volume:66
-
Issue:27
-
Collection(s):
-
Main Document Checksum:urn:sha-512:958208121246fa3b5cc78e4d676a9d793381432f7f8a62506cc9770429a93f568b9aaa4d3a3200a241119d02272eb30313cc7727b48f45557b3c849630d8226a
-
Download URL:
-
File Type:
Supporting Files
ON THIS PAGE
CDC STACKS serves as an archival repository of CDC-published products including
scientific findings,
journal articles, guidelines, recommendations, or other public health information authored or
co-authored by CDC or funded partners.
As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
You May Also Like
COLLECTION
Morbidity and Mortality Weekly Report (MMWR)